[
  {
    "ts": "2026-02-25T01:15:25+00:00",
    "headline": "Why Eli Lilly Stock Slumped Today",
    "summary": "Investors worried that the company could take quite a revenue hit due to a competitor's move.",
    "url": "https://www.fool.com/investing/2026/02/24/why-eli-lilly-stock-slumped-today/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "2e66560f-1dd1-3a2b-9f89-0b2c31ce3255",
      "content": {
        "id": "2e66560f-1dd1-3a2b-9f89-0b2c31ce3255",
        "contentType": "STORY",
        "title": "Why Eli Lilly Stock Slumped Today",
        "description": "",
        "summary": "Investors worried that the company could take quite a revenue hit due to a competitor's move.",
        "pubDate": "2026-02-25T01:15:25Z",
        "displayTime": "2026-02-25T01:15:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/0d11ab642e40bc0f6c99b7e07085c2ef",
          "originalWidth": 1400,
          "originalHeight": 683,
          "caption": "Person in lab gear looking through a microscope.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/etNdo1t.8L5zLK_gCH9c9Q--~B/aD02ODM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/0d11ab642e40bc0f6c99b7e07085c2ef.cf.webp",
              "width": 1400,
              "height": 683,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6VUVujFcQVXRmg3n5b7EtQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/0d11ab642e40bc0f6c99b7e07085c2ef.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/24/why-eli-lilly-stock-slumped-today/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-eli-lilly-stock-slumped-011525647.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T13:01:03+00:00",
    "headline": "Novo Nordisk's Loss Is Eli Lilly's Gain",
    "summary": "Eli Lilly and Company (NYSE:LLY) shares are up on Monday as the company benefits from positive market sentiment following Novo Nordisk A/S’ (NYSE:NVO) disappointing trial results for a weight-loss drug, adding pressure as broader markets edged lower. Eli Lilly Gains as Novo Nordisk Trial Setback Novo Nordisk’s stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly’s tirzepatide, marketed under the Zepbound and Mounjaro brands",
    "url": "https://finance.yahoo.com/news/novo-nordisks-loss-eli-lillys-130103846.html",
    "source": "Benzinga",
    "provider": "yfinance",
    "raw": {
      "id": "598577b8-c4ae-3908-af01-7676cb7d0216",
      "content": {
        "id": "598577b8-c4ae-3908-af01-7676cb7d0216",
        "contentType": "STORY",
        "title": "Novo Nordisk's Loss Is Eli Lilly's Gain",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) shares are up on Monday as the company benefits from positive market sentiment following Novo Nordisk A/S’ (NYSE:NVO) disappointing trial results for a weight-loss drug, adding pressure as broader markets edged lower. Eli Lilly Gains as Novo Nordisk Trial Setback Novo Nordisk’s stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly’s tirzepatide, marketed under the Zepbound and Mounjaro brands",
        "pubDate": "2026-02-25T13:01:03Z",
        "displayTime": "2026-02-25T13:01:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Benzinga/abbaaecb0fde99ee3964b9d76b965665",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IUU._bBhgVBKB51v8QU4QQ--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/abbaaecb0fde99ee3964b9d76b965665.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u28Izd0a40lCOZ5kJER0Ig--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/abbaaecb0fde99ee3964b9d76b965665.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Benzinga",
          "url": "http://www.benzinga.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-loss-eli-lillys-130103846.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-loss-eli-lillys-130103846.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]